我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.
Cas No.: |
1883423-59-3 |
名称: |
|
别名: |
|
SMILES: |
O=C(N1[C@H](C2=CC=C(Cl)C=C2)CCC1)C3=CN=C(NN=C4C)C4=C3 |
分子式: |
C18H17ClN4O |
分子量: |
340.81 |
纯度: |
|
保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: |
|
In Vivo: |
|
In Vitro: |
|
References: |
In vitro:
MSC2530818 binds to CDK8 and CDK19 with similar affinity (4 nM) and shows potent inhibition of phospho-STAT1SER727 in SW620 human colorectal carcinoma cells (IC50=8 ± 2 nM). It also demonstrates potent inhibition of WNT-dependent transcription in human cancer cell lines that have constitutively activated WNT signaling. MSC2530818 is a soluble CDK8 inhibitor with high permeability and low efflux ratio in Caco-2 cells (ER = 1.5) and does not inhibit any cytochrome P450 subtypes (Cyp IC50s > 20 μM).
In vivo: MSC2530818 shows acceptable pharmacokinetics (PK) in all tested preclinical species (mouse, rat, dog). It demonstrates reduction of tumor growth rates of established human SW620 colorectal carcinoma xenografts. |
Kinase Assay: |
|
Cell Assay: |
|
Animal Administration: |
|
References: |
|
MSDS
COA
LOT NO. |
DOWNLOAD |
|
|
2018-0101 |
|
询盘